This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Primary research
MiR-103 Assumes Signifying Capacity in Prostate Cancer Diagnosis
Tongzu Liu
Zhongnan Hospital of Wuhan University
Corresponding Author
ORCiD: https://orcid.org/0000-0002-9568-9036
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Prostate cancer is one of the common cancers among males with high incidence and mortality. MiR-103 has been reported to be involved in several human cancers. In our study, we aimed to explore the diagnostic value of miR-103 in PCa.
Methods: In this study, qRT-PCR was performed to investigate the expression levels of miR-103 in serum specimens collected from 141 PCa patients and 77 healthy volunteers. MTT and cell invasion assay were performed to detect the effects of miR-103 on the proliferation and invasion of PCa cells. The diagnostic value of miR-103 in PCa was evaluated by ROC curve.
Results: The results showed that serum miR-103 levels were higher in PCa patients than that in healthy group (P<0.001). And the expression of miR-103 was significantly associated with PSA (P=0.007), differentiation (P=0.009), and lymph node metastasis (P=0.037). Cell experiments in vitro demonstrated that miR-103 could promote PCa cell line proliferation and invasion. In addition, ROC analysis suggested that miR-103 could discriminate between PCa patients and healthy individuals at the cut-off value of 0.970. The AUC was 0.885, with the sensitivity of 97.2% and specificity of 81.8%.
Conclusions: The increased miR-103 levels can promote proliferation and invasion of PCa cells. Serum miR-103 is significantly associated with tumor progression, which may be a novel biomarker for PCa diagnosis.
Keywords
MiR-103, Prostate cancer, Diagnosis
Figure 1
Figure 2
Figure 3
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 17 Aug, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This is a preprint. It has not completed peer review.
Primary research
MiR-103 Assumes Signifying Capacity in Prostate Cancer Diagnosis
Tongzu Liu
Zhongnan Hospital of Wuhan University
Corresponding Author
ORCiD: https://orcid.org/0000-0002-9568-9036
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 17 Aug, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Prostate cancer is one of the common cancers among males with high incidence and mortality. MiR-103 has been reported to be involved in several human cancers. In our study, we aimed to explore the diagnostic value of miR-103 in PCa.
Methods: In this study, qRT-PCR was performed to investigate the expression levels of miR-103 in serum specimens collected from 141 PCa patients and 77 healthy volunteers. MTT and cell invasion assay were performed to detect the effects of miR-103 on the proliferation and invasion of PCa cells. The diagnostic value of miR-103 in PCa was evaluated by ROC curve.
Results: The results showed that serum miR-103 levels were higher in PCa patients than that in healthy group (P<0.001). And the expression of miR-103 was significantly associated with PSA (P=0.007), differentiation (P=0.009), and lymph node metastasis (P=0.037). Cell experiments in vitro demonstrated that miR-103 could promote PCa cell line proliferation and invasion. In addition, ROC analysis suggested that miR-103 could discriminate between PCa patients and healthy individuals at the cut-off value of 0.970. The AUC was 0.885, with the sensitivity of 97.2% and specificity of 81.8%.
Conclusions: The increased miR-103 levels can promote proliferation and invasion of PCa cells. Serum miR-103 is significantly associated with tumor progression, which may be a novel biomarker for PCa diagnosis.
Figure 1
Figure 2
Figure 3